@article {7681,
	title = {Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2},
	journal = {Anticancer Research},
	volume = {32},
	year = {2012},
	note = {Cited By :1Export Date: 21 February 2017},
	month = {2012},
	pages = {175 - 181},
	abstract = {Aim: The purpose of this study was to compare two single agents paclitaxel (intravenous) versus vinorelbine (oral) in non-small cell lung cancer (NSCLC) patients with performance status (PS):2. Patients and Methods: The patients were randomized to receive either oral vinorelbine 60 mg/m 2 on days I, 8, 15 every 4 weeks for 4 cycles (group A) or paclitaxel 90 mg/m 2 intravenously for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B). Results: Among the 74 eligible patients (36 in arm A and 38 in arm B) in arm A, two (6\%) had a partial response (95\% Cl, 0.7-18.7) and 5 (14\%) had stable disease (95\% CI, 4.7-29.5). In arm B, five (13\%) had a partial response (95\% CI, 4.4-28.1) and 7 (18\%) had stable disease (95\% CI, 7.7-34.3). No significant difference was found in terms of clinical benefit between the two groups after two cycles of treatment except for appetite in favour of paclitaxel (p=0.01). Median survival was 3.1 months (95\% CI, 2.2-4.0) for arm A and 5.1 months (95\% CI, 2.7-7.6) for arm B (p=0.95). Toxicity was mild and only alopecia was more profound in the patients of arm B (p=0.008). Conclusion: No significant difference was found in clinical benefit between PS:2 NSCLC patients treated with either vinorelbine or paclitaxel.},
	keywords = {Chemotherapy, Clinical benefit, Non-small cell lung cancer, Paclitaxel, Performance status of 2, Vinorelbine},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84855711471\&partnerID=40\&md5=9bb6b24567ae257c44d8de44df3ba69c},
	author = {Kosmidis, P.A. and Syrigos, K. and Kalofonos, H.P. and Dimopoulos, M.-A. and Skarlos, D. and N. Pavlidis and Boukovinas, I. and Bafaloukos, D. and Pectasides, D. and Bacoyiannis, C. and Fountzilas, G.}
}
